CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Clear cell renal cell carcinoma (ccRCC) has limited treatment options.
• Chimeric antigen receptor (CAR) T-cell therapy is a potential novel approach for solid tumors.

Purpose of the Study:

• To evaluate the safety and efficacy of CTX130, an allogeneic CD70-targeting CAR T-cell product, in patients with advanced or refractory ccRCC.
• To explore the potential of CD70-targeted CAR T-cells for treating ccRCC and other CD70+ malignancies.

Main Methods:

• Preclinical studies of CTX130 in RCC xenograft models.
• Phase I, multicenter, first-in-human clinical trial of CTX130 in 16 patients with relapsed/refractory ccRCC.
• Evaluation of a next-generation CAR T construct, CTX131, in preclinical studies.

Main Results:

• CTX130 demonstrated favorable preclinical proliferation, cytotoxicity, and complete regression of RCC xenograft tumors.
• In the phase I trial, no dose-limiting toxicity was observed, and 81.3% of patients achieved disease control.
• One patient achieved a durable complete response lasting 3 years. CTX131 showed improved preclinical expansion and efficacy.

Conclusions:

• Allogeneic CD70-targeted CAR T-cells represent a proof of concept for treating ccRCC and other CD70+ malignancies.
• This study provides the first complete response in a patient with RCC, highlighting the potential of CAR T-cell therapy in solid tumors.